SMTI Quote, Financials, Valuation and Earnings

Daxor Corp. has a net margin of 3.17% compared to Sanara MedTech, Inc.'s net margin of --. Sanara MedTech, Inc.'s return on equity of -20.48% beat Daxor Corp.'s return on equity of 1.57%.

Sanara MedTech, Inc. has a consensus price target of $41.00, signalling upside risk potential of 88.07%. On the other hand Daxor Corp. has an analysts' consensus of $22.00 which suggests that it could grow by 71.21%. Given that Sanara MedTech, Inc. has higher upside potential than Daxor Corp., analysts believe Sanara MedTech, Inc. is more attractive than Daxor Corp..

Sanara MedTech, Inc. has a beta of 1.182, which suggesting that the stock is 18.199% more volatile than S&P 500. In comparison Daxor Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100.015%.

Sanara MedTech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Daxor Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanara MedTech, Inc. pays -- of its earnings as a dividend. Daxor Corp. pays out -- of its earnings as a dividend.

Sanara MedTech, Inc. quarterly revenues are $26.3M, which are larger than Daxor Corp. quarterly revenues of --. Sanara MedTech, Inc.'s net income of $834.5K is higher than Daxor Corp.'s net income of --. Notably, Sanara MedTech, Inc.'s price-to-earnings ratio is -- while Daxor Corp.'s PE ratio is 35.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanara MedTech, Inc. is 1.84x versus 59.58x for Daxor Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Phibro Animal Health Corp. has a net margin of 3.17% compared to Sanara MedTech, Inc.'s net margin of 7.29%. Sanara MedTech, Inc.'s return on equity of -20.48% beat Phibro Animal Health Corp.'s return on equity of 24.77%.

Sanara MedTech, Inc. has a consensus price target of $41.00, signalling upside risk potential of 88.07%. On the other hand Phibro Animal Health Corp. has an analysts' consensus of $43.00 which suggests that it could grow by 5.47%. Given that Sanara MedTech, Inc. has higher upside potential than Phibro Animal Health Corp., analysts believe Sanara MedTech, Inc. is more attractive than Phibro Animal Health Corp..

Sanara MedTech, Inc. has a beta of 1.182, which suggesting that the stock is 18.199% more volatile than S&P 500. In comparison Phibro Animal Health Corp. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.868%.

Sanara MedTech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phibro Animal Health Corp. offers a yield of 1.18% to investors and pays a quarterly dividend of $0.12 per share. Sanara MedTech, Inc. pays -- of its earnings as a dividend. Phibro Animal Health Corp. pays out 40.46% of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanara MedTech, Inc. quarterly revenues are $26.3M, which are smaller than Phibro Animal Health Corp. quarterly revenues of $363.9M. Sanara MedTech, Inc.'s net income of $834.5K is lower than Phibro Animal Health Corp.'s net income of $26.5M. Notably, Sanara MedTech, Inc.'s price-to-earnings ratio is -- while Phibro Animal Health Corp.'s PE ratio is 24.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanara MedTech, Inc. is 1.84x versus 1.19x for Phibro Animal Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Precision Optics Corp., Inc. has a net margin of 3.17% compared to Sanara MedTech, Inc.'s net margin of -24.5%. Sanara MedTech, Inc.'s return on equity of -20.48% beat Precision Optics Corp., Inc.'s return on equity of -54.55%.

Sanara MedTech, Inc. has a consensus price target of $41.00, signalling upside risk potential of 88.07%. On the other hand Precision Optics Corp., Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Sanara MedTech, Inc. has higher upside potential than Precision Optics Corp., Inc., analysts believe Sanara MedTech, Inc. is more attractive than Precision Optics Corp., Inc..

Sanara MedTech, Inc. has a beta of 1.182, which suggesting that the stock is 18.199% more volatile than S&P 500. In comparison Precision Optics Corp., Inc. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.404%.

Sanara MedTech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precision Optics Corp., Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanara MedTech, Inc. pays -- of its earnings as a dividend. Precision Optics Corp., Inc. pays out -- of its earnings as a dividend.

Sanara MedTech, Inc. quarterly revenues are $26.3M, which are larger than Precision Optics Corp., Inc. quarterly revenues of $6.7M. Sanara MedTech, Inc.'s net income of $834.5K is higher than Precision Optics Corp., Inc.'s net income of -$1.6M. Notably, Sanara MedTech, Inc.'s price-to-earnings ratio is -- while Precision Optics Corp., Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanara MedTech, Inc. is 1.84x versus 1.40x for Precision Optics Corp., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Warby Parker, Inc. has a net margin of 3.17% compared to Sanara MedTech, Inc.'s net margin of 2.65%. Sanara MedTech, Inc.'s return on equity of -20.48% beat Warby Parker, Inc.'s return on equity of 0.2%.

Sanara MedTech, Inc. has a consensus price target of $41.00, signalling upside risk potential of 88.07%. On the other hand Warby Parker, Inc. has an analysts' consensus of $22.45 which suggests that it could grow by 20.34%. Given that Sanara MedTech, Inc. has higher upside potential than Warby Parker, Inc., analysts believe Sanara MedTech, Inc. is more attractive than Warby Parker, Inc..

Sanara MedTech, Inc. has a beta of 1.182, which suggesting that the stock is 18.199% more volatile than S&P 500. In comparison Warby Parker, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Sanara MedTech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Warby Parker, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanara MedTech, Inc. pays -- of its earnings as a dividend. Warby Parker, Inc. pays out -- of its earnings as a dividend.

Sanara MedTech, Inc. quarterly revenues are $26.3M, which are smaller than Warby Parker, Inc. quarterly revenues of $221.7M. Sanara MedTech, Inc.'s net income of $834.5K is lower than Warby Parker, Inc.'s net income of $5.9M. Notably, Sanara MedTech, Inc.'s price-to-earnings ratio is -- while Warby Parker, Inc.'s PE ratio is 4,847.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanara MedTech, Inc. is 1.84x versus 2.67x for Warby Parker, Inc.. Usually stocks with elevated PS ratios are considered overvalued.